Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

Looking back on generic pharmaceuticals stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amphastar Pharmaceuticals (NASDAQ...

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 15.8% in the afternoon session after the company reported fourth-quarter 2025 financial results that fell short of Wall Street's expectations on both revenue and profit. 

Amphastar (AMPH) Q4 2025 Earnings Call Transcript

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 1.8% year on year to $183.1 million. Its non-GAAP profit of $0.73 per share was 20.5% below analysts’ consensus estimates.

Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent® HFA Inhalation Aerosol.

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the market closes on Thursday, February 26, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. While the market's reaction was initially described as a "bumpy ride" due to concerns in other sectors, the favorable inflation data ultimately helped calm Wall Street. Lower inflation is a key prerequisite for the central bank to ease its monetary policy, which is generally supportive of stock valuations.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.3% in the afternoon session after a Bank of America analyst lowered the firm's price target on the shares and reports highlighted significant challenges in the company's product portfolio. The analyst trimmed the price target to $30 from $31 while keeping a Neutral rating. 

Amphastar Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.5%. The stock now trades at $27.76, marking a 31% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a new drug compound. 

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14th, 2026, at 2:15 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.

Amphastar is down big in 2025, but recently announced positive FDA-related news.